IndieBio

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

Vitarka Therapeutics is a London-based company focused on developing medical technologies and solutions for various types of cancer. The company has created a targeted non-viral delivery platform aimed at intracellular targets in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage patients suffering from lung, colon, breast, and other cancers. By utilizing re-engineered pore-forming proteins for cell-specific targeting and facilitating the endosomal release of therapeutic cargo, Vitarka Therapeutics aims to provide cancer patients with renewed hope and the potential to lead more normal lives.

Laguna Bio is a biotechnology company based in Berkeley, California, founded in 2022. The company focuses on drug discovery, specifically developing a platform that activates and expands the innate immune system to combat cancer. Laguna Bio specializes in enhancing a specific type of T cell that targets solid tumors, aiming to improve the efficacy of bispecific antibody drugs. By increasing the immune response against these tumors, the company seeks to provide innovative solutions that may help patients survive cancer more effectively.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

DisperseBio is a Biotechnology Research firm developing a mechanism to counter microbial contamination on natural surfaces like human body.

Metabolic Psychiatry Labs is a mental healthcare company that provides remote treatment solutions for mental illnesses. Their platform integrates metabolic and mental health research, data tracking, metabolic interventions, and personalized medical care, enabling patients to receive effective treatments from home. The company offers assessments, lab tests, and wellness solutions based on metabolic therapy.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Asta Bio is a biotechnology company specializing in the development of radiotherapeutics for cancer treatment. It focuses on combining the alpha-emitting radioisotope 211-Astatine with multivalent single-domain antibodies to deliver targeted alpha radiation to tumor cells, sparing healthy cells. This approach aims to effectively destroy cancer cells by breaking their DNA strands.

Tinkeso Therapeutics is a biotechnology company specializing in the development of innovative cell therapies for treating cancer and autoimmune diseases. The company focuses on creating off-the-shelf, allogeneic chimeric antigen receptor (CAR) engineered natural killer T (NKT) cell therapies. These therapies use NKT cells to target and destroy cancer cells or modulate the immune response in autoimmune conditions, aiming to increase treatment accessibility and scalability.

heXem bio specializes in recording solutions for the early development of humans for longevity.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to detect and eliminate cancer from within the body. The company is dedicated to advancing scientific breakthroughs that lead to new classes of treatments, providing significant improvements in medicine. RyboDyn's work is particularly concentrated on creating upgraded therapies for serious diseases, including terminal conditions, with the goal of enhancing patient outcomes and expanding treatment options.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies for the treatment of various human diseases, with a particular focus on oncology. The company has created a blood stem cell-derived epigenetic platform designed to address challenges related to donor source availability, cellular potency, and the complexities of manufacturing clinical-grade cell products. By leveraging this innovative platform, Cell BioEngines aims to produce cell-based therapies that can provide long-lasting benefits to patients, ultimately striving to transform cancer into a curable disease.

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

TippingPoint Biosciences is focused on developing therapeutics that address diseases linked to defects in DNA packaging, including various cancers and neurodegenerative disorders. Utilizing a drug discovery platform, the company aims to identify innovative treatments that specifically target unique genome packaging states associated with these diseases. This approach not only facilitates the treatment of cancers but also supports the development of stem cell therapies by addressing the underlying issues of dysfunctional genome packaging. Through its efforts, TippingPoint Biosciences seeks to advance medical care and improve patient outcomes in complex genetic conditions.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles that can be genetically engineered, manufactured, and purified. Diadem's innovative platform focuses on signaling through validated targets, offering potential treatments for various chronic inflammatory and autoimmune conditions, as well as cancers. By leveraging these technologies, Diadem aims to provide clinicians with effective solutions for managing immunopathologies.

Care Constitution is a telehealth service that provides a platform for clients to access health checkups online. The company focuses on improving healthcare delivery by assisting doctors with diagnostic testing through the use of artificial intelligence technology. This innovative approach aims to set a standard of care in medicine by offering objective, reproducible, and quantitative healthcare assessments. By enhancing the accuracy of diagnoses, Care Constitution seeks to support healthcare professionals in delivering better patient outcomes.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

Vitarka Therapeutics is a London-based company focused on developing medical technologies and solutions for various types of cancer. The company has created a targeted non-viral delivery platform aimed at intracellular targets in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage patients suffering from lung, colon, breast, and other cancers. By utilizing re-engineered pore-forming proteins for cell-specific targeting and facilitating the endosomal release of therapeutic cargo, Vitarka Therapeutics aims to provide cancer patients with renewed hope and the potential to lead more normal lives.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Aluna, established in 2013 and headquartered in San Francisco, specializes in developing medical devices and digital health platforms for managing chronic respiratory conditions, primarily asthma. The company's core product is a portable spirometry device that connects with an interactive iPhone game, enabling users, especially children, to track and monitor their asthma symptoms, medication, and potential triggers in real-time. This data is shared with healthcare providers, facilitating personalized treatment plans and early intervention. Aluna's mission is to empower patients to understand and manage their lung health, improving overall asthma outcomes.

BioROSA Technologies Inc. is a Belmont, Massachusetts-based company focused on developing blood tests for Autism Spectrum Disorders (ASD). Founded in 2018, the company aims to establish a biologically-based standard of care for ASD through innovative diagnostic tools. These tools enable clinicians to identify individuals at risk for ASD by utilizing blood-based biomarkers and advanced machine learning techniques. BioROSA’s platform not only enhances early detection and diagnosis but also supports therapeutic developments by facilitating patient stratification and assessing pharmacodynamics in clinical trials. This comprehensive approach equips healthcare professionals with the necessary resources to improve patient outcomes through timely intervention.

Free to Feed specializes in providing innovative solutions for breastfeeding mothers concerned about food allergies in their infants. The company has developed an over-the-counter allergen test that identifies various food proteins in breast milk, catering to mothers who suspect their babies may have food allergies or those who wish to introduce allergens early as recommended by pediatric guidelines. This product, complemented by the Free to Feed app, allows mothers to track allergens present in their milk, record nursing times, and document any infant symptoms, thereby generating valuable data for medical professionals. This approach aligns with evolving studies suggesting that early and consistent introduction of allergens may reduce the risk of developing allergies. By offering patented allergen testing kits, a proprietary algorithm, and tailored counseling, Free to Feed supports parents in confidently navigating their breastfeeding journey while addressing concerns about infant food intolerance.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Vitarka Therapeutics is a London-based company focused on developing medical technologies and solutions for various types of cancer. The company has created a targeted non-viral delivery platform aimed at intracellular targets in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage patients suffering from lung, colon, breast, and other cancers. By utilizing re-engineered pore-forming proteins for cell-specific targeting and facilitating the endosomal release of therapeutic cargo, Vitarka Therapeutics aims to provide cancer patients with renewed hope and the potential to lead more normal lives.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Laguna Bio is a biotechnology company based in Berkeley, California, founded in 2022. The company focuses on drug discovery, specifically developing a platform that activates and expands the innate immune system to combat cancer. Laguna Bio specializes in enhancing a specific type of T cell that targets solid tumors, aiming to improve the efficacy of bispecific antibody drugs. By increasing the immune response against these tumors, the company seeks to provide innovative solutions that may help patients survive cancer more effectively.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.

Conan MedTech, founded in 2020 and based in Ithaca, New York, specializes in the development of rapid point-of-care diagnostic tests for concussions. The company's innovative system is designed to facilitate real-time concussion detection, enabling sports medicine doctors, athletic coaches, and trainers to make informed decisions during games. By providing advanced and efficient medical assistance, Conan MedTech aims to enhance the diagnosis of mild traumatic brain injuries, ultimately improving patient care and outcomes.

Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

ArgenTag is a biotech startup focused on democratizing genomic sequencing through innovative technology. The company has developed a robust solution that significantly reduces the costs associated with long-read sequencing applications. By integrating micro-fabrication, next-generation DNA sequencing, molecular biology, and mechanical engineering, ArgenTag's platform produces synthetic DNA barcodes, allowing for the simultaneous sequencing of thousands of samples. This technology enables medical professionals to analyze antibodies and perform single-cell sequencing, making advanced genomic analysis more accessible to a broader audience.

ArgenTag is a biotech startup focused on democratizing genomic sequencing through innovative technology. The company has developed a robust solution that significantly reduces the costs associated with long-read sequencing applications. By integrating micro-fabrication, next-generation DNA sequencing, molecular biology, and mechanical engineering, ArgenTag's platform produces synthetic DNA barcodes, allowing for the simultaneous sequencing of thousands of samples. This technology enables medical professionals to analyze antibodies and perform single-cell sequencing, making advanced genomic analysis more accessible to a broader audience.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Cellens is a medical device company based in Medford, Massachusetts, that specializes in noninvasive cancer screening, particularly for bladder cancer. Founded in 2019 as a spinoff from Tufts University, the company has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning. This innovative platform analyzes physio-biomarkers on cell surfaces obtained from urine samples, generating a diagnostics score for bladder cancer. By providing oncologists and urologists with a reliable and less invasive alternative to traditional diagnostic methods, Cellens aims to enhance patient outcomes and reduce the need for costly and invasive procedures.

Cellens is a medical device company based in Medford, Massachusetts, that specializes in noninvasive cancer screening, particularly for bladder cancer. Founded in 2019 as a spinoff from Tufts University, the company has developed a cell surface scanning platform that utilizes atomic force microscopy imaging and machine learning. This innovative platform analyzes physio-biomarkers on cell surfaces obtained from urine samples, generating a diagnostics score for bladder cancer. By providing oncologists and urologists with a reliable and less invasive alternative to traditional diagnostic methods, Cellens aims to enhance patient outcomes and reduce the need for costly and invasive procedures.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can inhibit or promote ferroptosis, a form of regulated cell death. By targeting this process, Prothegen seeks to provide effective therapeutic options for patients, enhancing the treatment of conditions associated with uncontrolled cell death.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can inhibit or promote ferroptosis, a form of regulated cell death. By targeting this process, Prothegen seeks to provide effective therapeutic options for patients, enhancing the treatment of conditions associated with uncontrolled cell death.

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles that can be genetically engineered, manufactured, and purified. Diadem's innovative platform focuses on signaling through validated targets, offering potential treatments for various chronic inflammatory and autoimmune conditions, as well as cancers. By leveraging these technologies, Diadem aims to provide clinicians with effective solutions for managing immunopathologies.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Free to Feed specializes in providing innovative solutions for breastfeeding mothers concerned about food allergies in their infants. The company has developed an over-the-counter allergen test that identifies various food proteins in breast milk, catering to mothers who suspect their babies may have food allergies or those who wish to introduce allergens early as recommended by pediatric guidelines. This product, complemented by the Free to Feed app, allows mothers to track allergens present in their milk, record nursing times, and document any infant symptoms, thereby generating valuable data for medical professionals. This approach aligns with evolving studies suggesting that early and consistent introduction of allergens may reduce the risk of developing allergies. By offering patented allergen testing kits, a proprietary algorithm, and tailored counseling, Free to Feed supports parents in confidently navigating their breastfeeding journey while addressing concerns about infant food intolerance.

Dalton Bioanalytics specializes in developing advanced analytical technology aimed at transforming blood analysis into a more efficient and cost-effective process. By digitizing the biochemical composition of blood, the company provides a comprehensive array of actionable health insights, addressing the limitations of traditional laboratory testing. This technology enables the monitoring of various plasma analytes, including proteins, lipids, electrolytes, and small molecules, through a single assay. Dalton Bioanalytics supports the scientific research community in exploring multi-omic biology, thereby facilitating the discovery, development, and delivery of precision medicine. Founded in 2019, the company is headquartered in Los Angeles, California.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Aluna, established in 2013 and headquartered in San Francisco, specializes in developing medical devices and digital health platforms for managing chronic respiratory conditions, primarily asthma. The company's core product is a portable spirometry device that connects with an interactive iPhone game, enabling users, especially children, to track and monitor their asthma symptoms, medication, and potential triggers in real-time. This data is shared with healthcare providers, facilitating personalized treatment plans and early intervention. Aluna's mission is to empower patients to understand and manage their lung health, improving overall asthma outcomes.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Advanced Microbubbles Inc specializes in developing microbubbles as ultrasound contrast agents for targeted drug delivery, particularly in overcoming significant biological barriers like the blood-brain barrier and tumor endothelium. Founded in 2020 and based in Newark, California, the company offers a range of products including size-isolated microbubbles, polydisperse microbubbles, and biotin- or streptavidin-tagged variants. These microbubbles are agitated with ultrasound at the tumor site, facilitating the local delivery of drugs by temporarily opening barriers that typically hinder treatment. By enabling more effective drug delivery, Advanced Microbubbles aims to reduce side effects and improve survival outcomes for patients with various neurological conditions and cancer.

Advanced Microbubbles Inc specializes in developing microbubbles as ultrasound contrast agents for targeted drug delivery, particularly in overcoming significant biological barriers like the blood-brain barrier and tumor endothelium. Founded in 2020 and based in Newark, California, the company offers a range of products including size-isolated microbubbles, polydisperse microbubbles, and biotin- or streptavidin-tagged variants. These microbubbles are agitated with ultrasound at the tumor site, facilitating the local delivery of drugs by temporarily opening barriers that typically hinder treatment. By enabling more effective drug delivery, Advanced Microbubbles aims to reduce side effects and improve survival outcomes for patients with various neurological conditions and cancer.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

Convalesce Inc. is a therapeutic company based in San Francisco, California, focused on developing stem cell-based therapies for neurodegenerative conditions, particularly Parkinson's disease. Founded in 2018, Convalesce utilizes advanced biomaterials to enhance the efficacy of stem cell treatments. Their innovative implantable biomaterials aim to improve stem cell survival and facilitate the differentiation of these cells into neurons after implantation. By addressing critical challenges in stem cell therapy, Convalesce seeks to enable healthcare professionals to regenerate neuronal networks lost due to degeneration, ultimately offering new hope for patients suffering from debilitating neurological disorders.

Dalton Bioanalytics specializes in developing advanced analytical technology aimed at transforming blood analysis into a more efficient and cost-effective process. By digitizing the biochemical composition of blood, the company provides a comprehensive array of actionable health insights, addressing the limitations of traditional laboratory testing. This technology enables the monitoring of various plasma analytes, including proteins, lipids, electrolytes, and small molecules, through a single assay. Dalton Bioanalytics supports the scientific research community in exploring multi-omic biology, thereby facilitating the discovery, development, and delivery of precision medicine. Founded in 2019, the company is headquartered in Los Angeles, California.

Membio's single-use 0.2-10 L benchtop bioreactor system uses a proprietary design to provide a constant environment for cells at all scales. One technique will provide the same outcomes at all scales, whether at 0.2 L, 10 L, or anywhere in between. Fully automated single-use bioreactors designed by the business to enable cost-effective and scalable manufacture.

Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.